Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Group Phase 2 Study to Investigate Pharmacokinetics, Safety and Tolerability of Cefepime-Enmetazobactam Administered by IV Over 2 Hr in Male or Female Participants From Birth to Less Than 18 Years of Age Hospitalised With cUTI

NCT05826990 is registered in ClinicalTrials.gov with Orchid Pharma Europe GmbH as lead sponsor.

NCT NCT05826990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05826990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Group Phase 2 Study to Investigate Pharmacokinetics, Safety and Tolerability of Cefepime-Enmetazobactam Administered by IV Over 2 Hr in Male or Female Participants From Birth to Less Than 18 Years of Age Hospitalised With cUTI
Lead sponsor
Orchid Pharma Europe GmbH
Phase
Phase 2
Overall status
Recruiting
Start date
September 11, 2023
Completion date
May 21, 2029
Enrollment
40 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

complicated urinary tract infection